This company listing is no longer active
7OT Stock Overview
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Otonomy, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.063 |
| 52 Week High | US$2.33 |
| 52 Week Low | US$0.022 |
| Beta | 1.53 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -96.91% |
| 3 Year Change | -96.60% |
| 5 Year Change | -98.00% |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7OT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -0.4% |
| 1Y | -96.9% | -27.1% | 5.0% |
Return vs Industry: 7OT underperformed the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: 7OT underperformed the German Market which returned -7% over the past year.
Price Volatility
| 7OT volatility | |
|---|---|
| 7OT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7OT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7OT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 51 | n/a | https://www.otonomy.com |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.
Otonomy, Inc. Fundamentals Summary
| 7OT fundamental statistics | |
|---|---|
| Market cap | €530.12k |
| Earnings (TTM) | -€47.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 7OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7OT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.26m |
| Earnings | -US$52.26m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 75.4% |
How did 7OT perform over the long term?
See historical performance and comparison